Ornidazole
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Ornidazole
- Accession Number
- DB13026
- Description
Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Ornidazole (DB13026)
- Weight
- Average: 219.63
Monoisotopic: 219.0410689 - Chemical Formula
- C7H10ClN3O3
- Synonyms
- ornidazol
Pharmacology
- Indication
- Not Available
- Associated Conditions
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAtracurium The therapeutic efficacy of Atracurium can be increased when used in combination with Ornidazole. Atracurium besylate The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Ornidazole. Cisatracurium The therapeutic efficacy of Cisatracurium can be increased when used in combination with Ornidazole. Decamethonium The therapeutic efficacy of Decamethonium can be increased when used in combination with Ornidazole. Doxacurium The therapeutic efficacy of Doxacurium can be increased when used in combination with Ornidazole. Gallamine triethiodide The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Ornidazole. Metocurine The therapeutic efficacy of Metocurine can be increased when used in combination with Ornidazole. Metocurine iodide The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Ornidazole. Mivacurium The therapeutic efficacy of Mivacurium can be increased when used in combination with Ornidazole. Pancuronium The therapeutic efficacy of Pancuronium can be increased when used in combination with Ornidazole. Additional Data Available- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - Severity
- Evidence Level
- ActionAction
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
Products
Categories
- ATC Codes
- G01AF06 — Ornidazole
- G01AF — Imidazole derivatives
- G01A — ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS
- G01 — GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS
- G — GENITO URINARY SYSTEM AND SEX HORMONES
- J01RA — Combinations of antibacterials
- J01R — COMBINATIONS OF ANTIBACTERIALS
- J01 — ANTIBACTERIALS FOR SYSTEMIC USE
- J — ANTIINFECTIVES FOR SYSTEMIC USE
- J01XD — Imidazole derivatives
- J01X — OTHER ANTIBACTERIALS
- J01 — ANTIBACTERIALS FOR SYSTEMIC USE
- J — ANTIINFECTIVES FOR SYSTEMIC USE
- P01AB — Nitroimidazole derivatives
- P01A — AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES
- P01 — ANTIPROTOZOALS
- P — ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
- J01RA — Combinations of antibacterials
- J01R — COMBINATIONS OF ANTIBACTERIALS
- J01 — ANTIBACTERIALS FOR SYSTEMIC USE
- J — ANTIINFECTIVES FOR SYSTEMIC USE
- Drug Categories
- Amebicides
- Anti-Infective Agents
- Antibacterials for Systemic Use
- Antiinfectives for Systemic Use
- Antiparasitic Agents
- Antiparasitic Products, Insecticides and Repellents
- Antiprotozoals
- Antitrichomonal Agents
- Genito Urinary System and Sex Hormones
- Gynecological Antiinfectives and Antiseptics
- Imidazole Derivatives
- Imidazoles
- Nitro Compounds
- Nitroimidazole Derivatives
- Nitroimidazoles
- Radiation-Sensitizing Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as nitroimidazoles. These are compounds containing an imidazole ring which bears a nitro group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Azoles
- Sub Class
- Imidazoles
- Direct Parent
- Nitroimidazoles
- Alternative Parents
- 1,2,5-trisubstituted imidazoles / Nitroaromatic compounds / N-substituted imidazoles / Heteroaromatic compounds / Secondary alcohols / Chlorohydrins / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Organic oxoazanium compounds / Organic oxides show 6 more
- Substituents
- 1,2,5-trisubstituted-imidazole / Alcohol / Alkyl chloride / Alkyl halide / Allyl-type 1,3-dipolar organic compound / Aromatic heteromonocyclic compound / Azacycle / C-nitro compound / Chlorohydrin / Halohydrin show 20 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- C-nitro compound, secondary alcohol, imidazoles, organochlorine compound (CHEBI:75176)
Chemical Identifiers
- UNII
- 62XCK0G93T
- CAS number
- 16773-42-5
- InChI Key
- IPWKIXLWTCNBKN-UHFFFAOYSA-N
- InChI
- InChI=1S/C7H10ClN3O3/c1-5-9-3-7(11(13)14)10(5)4-6(12)2-8/h3,6,12H,2,4H2,1H3
- IUPAC Name
- 1-chloro-3-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-2-ol
- SMILES
- CC1=NC=C(N1CC(O)CCl)N(=O)=O
References
- General References
- TITCK Product Information: Bitazol (ornidazole) solution for infusion [Link]
- TITCK Product Information: Bitazol (ornidazole) film-coated tablets [Link]
- TITCK Product Information: Bitazol (ornidazole) vaginal tablets [Link]
- TITCK Product Information: Ornisasin (ornidazole/ciprofloxacin hydrochloride) film-coated tablets [Link]
- External Links
- PubChem Compound
- 28061
- PubChem Substance
- 347829160
- ChemSpider
- 26102
- 7701
- ChEBI
- 75176
- ChEMBL
- CHEMBL1449676
- Wikipedia
- Ornidazole
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Prevention Elective Colorectal Surgery 1 3 Recruiting Prevention Malignant Neoplasm of Colon 1 3 Recruiting Prevention Rectal Cancer Surgery 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, film coated 500 mg Tablet, film coated 250 mg Suppository Vaginal 500 mg Injection, solution Intravenous 500 mg Tablet, coated 250 mg Tablet, coated 500 mg Solution Intravenous 500 mg/3ml Solution Parenteral 500 mg/3ml Tablet, film coated Oral 500 mg Injection, solution Intravenous 500 mg/3ml Injection Intravenous 500 mg/3ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 3.34 mg/mL ALOGPS logP 0.37 ALOGPS logP 0.26 ChemAxon logS -1.8 ALOGPS pKa (Strongest Acidic) 13.89 ChemAxon pKa (Strongest Basic) 3.08 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 83.87 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 50.23 m3·mol-1 ChemAxon Polarizability 19.59 Å3 ChemAxon Number of Rings 1 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-00fr-0590000000-51e17e00bdee7b7e70f6 MS/MS Spectrum - , positive LC-MS/MS splash10-00fr-1590000000-10d4a11d06fa5ff22012 MS/MS Spectrum - , positive LC-MS/MS splash10-004i-3911000000-5b4872e026a447ba42bd
Drug created on October 20, 2016 20:10 / Updated on October 22, 2020 14:10
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg","CS-Molecular-Health-2.jpg":"/assets/ads/CS-Molecular-Health-2-22f41f94b3f87e44a1dcaa8f6c03dc411ab69558efd4f3148ff9bb6adaa956dc.jpg","PM-5.jpg":"/assets/ads/PM-5-d0dc031e0fa0d0097d912eff07b7e80b27b867264dd5b055e379a57bfa2a8723.jpg","DDI-4.jpg":"/assets/ads/DDI-4-313b9c374b937fd78bb2ade652b9b030abb9e6cb90efd35833f793e384e8185b.jpg","Discover-1.jpg":"/assets/ads/Discover-1-b48ae6a3872eeb442f4c22a9a1d867428c83a917ec78a8c3ff4e02f84c5d4fef.jpg","Discover-2.jpg":"/assets/ads/Discover-2-6e7759998ee0fdc234cd84eea962f2480f0c7dafadabd785924918420decb102.jpg","Repurpose-1.jpg":"/assets/ads/Repurpose-1-265fbec40f0eac18d51d3ec4f558c10cb623d834ea75e0296259e458b72ee6d4.jpg","Repurpose-2.jpg":"/assets/ads/Repurpose-2-d12bd1d18b92d36eab60e71e6fd59acf04ef60a53783570e11eef397a0e0f4f5.jpg","PM-6.jpg":"/assets/ads/PM-6-3ae66e41f7ae1e851a0910be89141cf2533509b46df6379464efc885d5ee2f07.jpg","Drug-Search-4.jpg":"/assets/ads/Drug-Search-4-2a9102bd41f16e8c40c9d8044d1dcb6f206ff80107cc269aa83d02ea683bc829.jpg","DDI-5.jpg":"/assets/ads/DDI-5-fa1c287946f4044094c723161577cb5ac631f9cd1217446e510dc79ace6cb94e.jpg","TH-1.jpg":"/assets/ads/TH-1-55a9077bb39e8c38a68c67b555b8091d21a9d41b1c21c7daed3fe53e6f9f3c97.jpg","TH-2.jpg":"/assets/ads/TH-2-1d488747fa4af00ab970a48dba0b228b054d166aa22c1760a310e2b72dd22589.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates